EMEIS SA

Emeis reported strong first-half 2026 results, with like-for-like revenue growth of 6% driven by a 2.8 percentage point increase in average occupancy rates to above 90% in the second quarter. Operating margins improved significantly, as EBITDA margin excluding IFRS 16 rose by 2.2 points to 7.6% and EBIT grew 83% year-on-year. The company's financial leverage ratio decreased dramatically to 8.7 times from 15.4 times a year ago, well ahead of its covenant commitment of 12 times by the end of 2026. Management raised its full-year 2026 guidance, now expecting like-for-like EBITDA growth of 12% to 14%, up from the previous forecast of slightly more than 10%. Net income remained negative at minus 40 million euros, though it improved by 97 million euros versus the prior year, while cash flow faced headwinds from non-recurring items including a 94 million euro working capital increase and 164 million euros in one-off safeguard-plan exit payments.

emeis has announced a series of senior appointments to its Executive Committee, effective from September and October 2026. Jean-Marc Boursier, currently Deputy CEO, has been named Chief Operating Officer and will oversee operations across all countries, with all country CEOs reporting to him; he will also serve as CEO for France. Sylvie Brisson will join as Group EVP of Human Resources from 1 October, replacing Fanny Barbier, who will stay until year-end to support the transition. Maria de la Mota has been appointed Group EVP, Medical, and Julia Clavel becomes Group Chief Financial Officer, both from 1 September. The changes are part of CEO Laurent Guillot's effort to support growth and improve care quality under the 'emeis 2030' project.